AstraZeneca is presenting a broad package of new clinical and [...]

AstraZeneca’s Imfinzi (durvalumab) has been recommended by NICE for use [...]

The National Institute for Health and Care Excellence (NICE) has [...]

Tozorakimab has met its primary endpoint in two replicate Phase [...]

AstraZeneca has received a positive recommendation from the Committee for [...]

Immunai has signed an agreement worth up to $85 million [...]

Thermo Fisher Scientific’s PPD clinical research business has entered into [...]

AstraZeneca and Amgen’s Tezspire (tezepelumab) has received a positive opinion [...]

AstraZeneca has reported positive interim results from the Phase 3 [...]